Back to top
more

Biogen Inc. (BIIB)

(Delayed Data from NSDQ)

$338.10 USD

338.10
1,212,713

+0.10 (0.03%)

Updated Aug 4, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (205 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for BIIB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Biogen Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 2,610 4,476 3,538 3,689 4,895
Receivables 1,914 1,881 1,959 1,787 1,442
Notes Receivable 0 0 0 0 0
Inventories 1,069 804 930 903 1,002
Other Current Assets 1,295 1,221 1,215 1,495 1,394
Total Current Assets 6,887 8,382 7,641 7,873 8,732
Net Property & Equipment 3,412 3,247 3,601 3,182 2,502
Investments & Advances 3,671 2,661 3,067 4,085 4,165
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1,370 3,232 2,154 0 0
Intangibles 8,846 9,285 8,826 8,512 7,478
Deposits & Other Assets 0 0 0 0 0
Total Assets 24,619 27,234 25,289 23,653 22,877
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 1,496 0 3 5
Accounts Payable 455 531 371 396 280
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 3,145 2,766 2,861 2,901 2,904
Income Taxes Payable 142 71 64 68 232
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 3,742 4,864 3,295 3,368 3,420
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1,033 2,811 1,636 123 93
Convertible Debt 0 0 0 0 0
Long-Term Debt 7,426 4,459 5,937 5,935 6,513
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,330 1,349 1,389 1,629 723
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 13,933 13,895 12,257 11,055 10,748
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 0 0 0 98 0
Retained Earnings 13,976 16,455 16,257 15,810 15,072
Other Equity -313 -139 -248 -333 -331
Treasury Stock 2,977 2,977 2,977 2,977 2,612
Total Shareholder's Equity 10,686 13,339 13,032 12,598 12,129
Total Liabilities & Shareholder's Equity 24,619 27,234 25,289 23,653 22,877
Total Common Equity 10,686 13,339 13,032 12,598 12,129
Shares Outstanding 153.80 180.40 201.40 211.50 215.90
Book Value Per Share 69.48 73.94 64.71 59.57 56.18

Fiscal Year End for Biogen Inc. falls in the month of December.

All items in Millions except Per Share data.

6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Assets          
Cash & Equivalents 3,051 2,538 2,610 3,580 4,328
Receivables 1,688 1,854 1,914 2,025 2,134
Notes Receivable 0 0 0 0 0
Inventories 1,255 1,172 1,069 1,028 953
Other Current Assets 1,190 1,156 1,295 1,211 1,080
Total Current Assets 7,184 6,720 6,887 7,843 8,494
Net Property & Equipment 3,442 3,438 3,412 3,360 3,331
Investments & Advances 3,443 3,245 3,671 2,845 2,406
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1,850 1,286 1,370 1,373 1,710
Intangibles 8,149 8,751 8,846 9,079 9,135
Deposits & Other Assets 0 0 0 0 0
Total Assets 24,470 23,855 24,619 24,934 25,512
Liabilities & Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Notes Payable 0 0 0 0 0
Accounts Payable 375 430 455 398 384
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 2,741 2,592 3,145 3,286 2,487
Income Taxes Payable 231 143 142 119 577
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 3,347 3,166 3,742 3,804 3,447
Mortgages 0 0 0 0 0
Deferred Taxes/Income 919 967 1,033 1,123 1,462
Convertible Debt 0 0 0 0 0
Long-Term Debt 7,269 7,267 7,426 7,425 7,424
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,356 1,330 1,428 1,475
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 13,256 13,192 13,933 14,190 14,223
Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 0 0 0 0 0
Retained Earnings 13,901 13,834 13,976 13,961 14,467
Other Equity 291 -193 -313 -240 -201
Treasury Stock 2,977 2,977 2,977 2,977 2,977
Total Shareholder's Equity 11,215 10,663 10,686 10,745 11,289
Total Liabilities & Shareholder's Equity 24,470 23,855 24,619 24,934 25,512
Total Common Equity 11,215 10,663 10,686 10,745 11,289
Shares Outstanding 149.00 150.50 153.80 153.80 158.30
Book Value Per Share 75.27 70.85 69.48 69.86 71.32